Lotus Pharmaceutical Co., Ltd. (TPE:1795)
Taiwan · Delayed Price · Currency is TWD 180.00
0.00 (0.00%)
Sep 18, 2026, 1:30 PM CST
Lotus Pharmaceutical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 48,544 | 74,423 | 71,524 | 71,935 | 64,462 | 25,569 | |
Market Cap Growth | -0.76% | 4.05% | -0.57% | 11.59% | 152.11% | 30.27% |
Enterprise Value | 100,665 | 81,170 | 80,276 | 81,666 | 71,660 | 30,851 |
Last Close Price | 180.00 | 275.65 | 255.66 | 253.41 | 226.52 | 88.48 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.66 | 15.77 | 14.12 | 17.52 | 21.34 | 18.22 |
Forward PE | 8.93 | 11.05 | 12.05 | 15.36 | 18.39 | 15.41 |
PS Ratio | 1.70 | 3.63 | 3.85 | 4.24 | 4.41 | 2.02 |
PB Ratio | 2.00 | 3.13 | 3.38 | 4.15 | 4.65 | 2.31 |
P/TBV Ratio | - | - | 7.26 | 11.65 | 28.14 | 10.18 |
P/FCF Ratio | 15.43 | 12.08 | 12.33 | 59.77 | 20.52 | - |
P/OCF Ratio | 10.79 | 9.95 | 11.62 | 44.56 | 17.33 | 213.68 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.53 | 3.96 | 4.32 | 4.82 | 4.90 | 2.44 |
EV/EBITDA Ratio | 10.76 | 10.67 | 10.95 | 13.23 | 14.07 | 9.63 |
EV/EBIT Ratio | 13.83 | 13.08 | 12.99 | 16.07 | 16.86 | 12.20 |
EV/FCF Ratio | 32.00 | 13.17 | 13.84 | 67.85 | 22.81 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 2.40 | 2.35 | 0.65 | 0.67 | 0.64 | 0.63 |
Debt / EBITDA Ratio | 6.25 | 7.23 | 1.83 | 1.84 | 1.72 | 2.12 |
Debt / FCF Ratio | 18.58 | 9.08 | 2.36 | 9.63 | 2.84 | - |
Net Debt / Equity Ratio | 2.14 | 2.03 | 0.36 | 0.57 | 0.50 | 0.48 |
Net Debt / EBITDA Ratio | 5.66 | 6.33 | 1.04 | 1.59 | 1.36 | 1.67 |
Net Debt / FCF Ratio | 16.57 | 7.82 | 1.32 | 8.15 | 2.21 | -11.78 |
Asset Turnover | 0.39 | 0.28 | 0.51 | 0.54 | 0.58 | 0.62 |
Inventory Turnover | 2.06 | 1.28 | 2.01 | 2.13 | 2.13 | 2.65 |
Quick Ratio | 0.88 | 0.92 | 1.63 | 1.85 | 1.17 | 1.16 |
Current Ratio | 1.46 | 1.57 | 2.15 | 2.80 | 1.81 | 1.93 |
Return on Equity (ROE) | 16.86% | 21.00% | 26.30% | 26.32% | 24.23% | 14.16% |
Return on Assets (ROA) | 6.20% | 5.30% | 10.57% | 10.16% | 10.47% | 7.71% |
Return on Invested Capital (ROIC) | 7.47% | 10.17% | 17.59% | 17.05% | 17.51% | 12.44% |
Return on Capital Employed (ROCE) | 8.00% | 7.00% | 19.50% | 17.90% | 18.00% | 15.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.76% | 6.34% | 7.08% | 5.71% | 4.69% | 5.49% |
FCF Yield | 6.48% | 8.28% | 8.11% | 1.67% | 4.88% | -1.77% |
Dividend Yield | 1.40% | 0.92% | 2.21% | 1.81% | 1.51% | 2.15% |
Payout Ratio | 18.04% | 32.20% | 24.32% | 22.07% | 16.75% | 6.56% |
Buyback Yield / Dilution | 0.69% | 0.67% | -0.53% | -0.13% | -1.95% | -5.43% |
Total Shareholder Return | 2.09% | 1.58% | 1.69% | 1.69% | -0.44% | -3.27% |